Close Menu

NEW YORK – Novartis on Wednesday announced that based on positive results from a planned interim analysis of the Phase II ELARA trial, it plans to file new US and EU regulatory submissions for its CAR T-cell therapy tisagenlecleucel (Kymriah) for patients with relapsed or refractory follicular lymphoma.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.